NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Tuesday that its third quarter revenues increased 25 percent year over year, beating Wall Street estimates on the top and bottom line.

The San Diego-based genetic analysis tools firm reported total revenues of $357 million, up from $285.9 million for Q3 2012, and surpassing the Wall Street consensus estimate for revenues of $343.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."